Microflora characteristics of oncological patients with postoperative infectious complications

Abstract

The microflora of the pathological material from patients with postoperative infections was studied and the resistance of isolated strains to antimicrobial agents was analyzed. The biological properties and antibacterial sensitivity of the bacterial strains isolated during the studies was assessed according to generally accepted methods that regulate the work of a microbiological laboratory. The study included 83 patients of the abdominal oncology department who underwent surgical treatment in 2017-2021. During this period, gram-negative microflora prevailed in the pathological material (p < 0.05): Acinetobacter baumannii, Citrobacter braakii, Enterobacter asburiae, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Pseudomonas putida, Proteus mirabilis, Serratia liquefaciens, Stenotrophomonas maltophilia. Kl. pneumoniae, E. coli and Acinetobacter baumannii were the leading pathogens. Gram-positive microflora in 2017-2021 was represented mainly by enterococci (E. faecalis, E. faecium and E. gallinarum) and staphylococci (S. hominis, S. haemolyticus, S. sciuri, S. epidermidis, S. aureus). E. coli was one of the dominant microorganisms within the period under study. The strains of this microorganism had polyresistance to the main antimicrobial drugs (ceftazidime, ampicillin, amoxicillin/clavulanate, trimethoprim/sulfamethoxazole, ciprofloxacin). E. coli strains remained susceptible to tigecycline, meropenem, and ceftazidime/avibactam. For prevention of postoperative complications in the abdominal oncology department, it is necessary to continue microbiological monitoring, strengthen the control of gram-negative microflora (as it is expected that it will remain the leading etiological agent of postoperative infections in this department) and use tigecycline, meropenem, and ceftazidime/avibactam for the treatment and prevention of postoperative complications caused by E. coli.